Скачать или смотреть Update on fixed-duration cohort of CAPTIVATE trial for CLL/SLL

Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, gives an update on the Phase II CAPTIVATE trial (NCT02910583), investigating ibrutinib plus venetoclax for patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). There were two patient cohorts; one in which the duration of treatment was guided by measurable residual disease (MRD) levels and the other in which there was a fixed duration of treatment. Dr Ghia discusses the results of the fixed-duration cohort who received 3 cycles of ibrutinib, followed by 12 cycles of ibrutinib plus venetoclax. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.